Modalis Therapeutics Partners With Ginkgo Bioworks, Enhancing Cell And Gene Therapy With CRISPR-GNDM Technology
Modalis Therapeutics Partners With Ginkgo Bioworks, Enhancing Cell And Gene Therapy With CRISPR-GNDM Technology
Modalis Joins Ginkgo's Technology Network
Modalis 加入 Ginkgo 的技术网络
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo's global customers in the cell and gene therapy fields to access Modalis' proprietary epigenome modulation technology, CRISPR-GNDM (Guide Nucleotide-Directed Modulation). Modalis' CRISPR-GNDM Technology is capable of activating or suppressing any gene in a controlled manner without requiring DNA cleavage. This collaboration also creates a significant opportunity for Modalis to establish additional strategic partnerships.
莫达利斯治疗公司（Modalis）（东京证券交易所：4883）宣布，它已与银杏生物工程公司（Ginkgo）签订协议，加入银杏科技网络。该战略联盟将使Ginkgo在细胞和基因疗法领域的全球客户能够获得Modalis专有的表观基因组调制技术CRISPR-GNDM（指导核苷酸定向调制）。莫达利斯的CRISPR-GNDM技术能够以可控的方式激活或抑制任何基因，而无需进行DNA裂解。这种合作还为Modalis建立更多战略伙伴关系创造了重要机会。
译文内容由第三方软件翻译。